Clostridium difficile immune globulin - Immuron

Drug Profile

Clostridium difficile immune globulin - Immuron

Alternative Names: DiffGAM™; IMM308

Latest Information Update: 23 Jan 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImmuCell
  • Developer Immuron
  • Class Antibacterials; Immunoglobulins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Clostridium infections

Most Recent Events

  • 23 Jan 2015 Discontinued - Phase-II for Clostridium infections in Australia (PO)
  • 30 Sep 2010 Phase-II clinical trials in Clostridium infections in Australia (PO)
  • 15 Jan 2003 DiffGAM technology has been licensed to CURx outside of Europe and certain nutritional rights in North America (www.curxpharma.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top